Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 25:10:35-41.
doi: 10.4137/CMO.S38204. eCollection 2016.

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Mohammed A Osman  1 , Mohammad S Elkady  2 , Khalid E Nasr  2
Affiliations

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

Mohammed A Osman et al. Clin Med Insights Oncol. .

Abstract

Introduction: Treatment of recurrent platinum-resistant ovarian and peritoneal cancers represents a therapeutic challenge. The aim of this Phase III prospective study was to compare the survival benefits, objective response rate, and toxicities among patients treated by weekly paclitaxel with those who underwent three-weekly paclitaxel in recurrent platinum-resistant ovarian and peritoneal cancers.

Method: Patients with recurrent platinum-resistant ovarian and peritoneal cancer were allocated to receive either weekly paclitaxel (arm 1) at 80 m/m(2) or three-weekly paclitaxel (arm 2) at 175 mg/m(2).

Results: Fifty-five patients were enrolled (30 arm 1, 25 arm 2). The mean age was 56.7 years, and the median performance status was 0 (Eastern Cooperative Oncology Group [ECOG]). For arms 1 and 2, the objective response rates were 27% and 16%, the median progression-free survival were 7 and 4.5 months, and the median overall survival were 15.5 and 12.5 months, respectively. Treatments also significantly improved the quality of life. Treatment was associated with mild toxicities, and while neuropathy was slightly higher for weekly paclitaxel over three-weekly paclitaxel, hematological toxicities were significantly lower for the former than the latter.

Conclusion: Paclitaxel rechallenge showed antitumor activity in recurrent platinum-resistant ovarian and peritoneal cancers. Weekly paclitaxel achieved better results than three-weekly paclitaxel in terms of survival benefits, quality of life, and toxicities.

Keywords: ORR; PFS; QOL; ovary; paclitaxel; platinum-resistant; weekly.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PFS for the study groups – P value: 0.02.
Figure 2
Figure 2
OS for the study groups – P value: 0.03.
Figure 3
Figure 3
QOl assessment for the study group.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E, Cancer WE. statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203. - PMC - PubMed
    1. Pujade-Lauraine E, Paraiso D, Cure H, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol. 2002:21. Abstract829.
    1. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. - PubMed
    1. BCCA Protocol Summary. 2010. Available at: http://www.bccancer.bc.ca/HPI/Drug-Database/DrugIndexPro/Paclitaxel.htm.

LinkOut - more resources